FDA expedites review of Biogen's multiple sclerosis drug

07/8/2009 | American City Business Journals

The FDA granted fast-track designation to Biogen Idec's PEGylated interferon beta-1a, a multiple sclerosis medicine. The drug's potential to treat patients with only one or two injections a month might have been a factor in the agency's decision. Biogen plans on "working closely with the FDA to expedite the compound's development and review process," a company official said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO